Abiopharma

🔍 Hartung Michael P (Executive)

Company: FLEX LTD. (FLEX)

Report Date: 2026-05-08

Detailed Transactions and Holdings:

• Acquired 43,724 shares of Ordinary Shares (Direct)
  Date: 2026-05-08 | Code: A | equity_swap_involved: 0 | shares_owned_after: 254,922.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,620 shares of Ordinary Shares at $138.6516 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 253,302.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 2,160 shares of Ordinary Shares at $139.6675 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 251,142.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Sold 2,129 shares of Ordinary Shares at $140.5852 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 249,013.00 | transaction_form_type: 4 | Footnotes: F2, F5
• Sold 1,888 shares of Ordinary Shares at $141.4893 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 247,125.00 | transaction_form_type: 4 | Footnotes: F2, F6
• Sold 5,260 shares of Ordinary Shares at $142.9357 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 241,865.00 | transaction_form_type: 4 | Footnotes: F2, F7
• Sold 6,623 shares of Ordinary Shares at $143.7609 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 235,242.00 | transaction_form_type: 4 | Footnotes: F2, F8
• Sold 2,536 shares of Ordinary Shares at $144.4482 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 232,706.00 | transaction_form_type: 4 | Footnotes: F2, F9, F10

Footnotes:

• F1: On June 14, 2023, the Reporting Person was awarded performance-based restricted share units ("PSUs") within a preset range, with the actual number contingent upon the achievement of a certain performance criterion with respect to the three-year performance period ending on March 31, 2026. The Issuer certified the achievement of the performance criterion, and the PSUs fully vested, on May 8, 2026, and were subject to applicable taxes upon delivery.
• F2: The sales reported in this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs.
• F3: Price reflects weighted average sales price; actual sales prices ranged from $138.11 to $139.08. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F4: Price reflects weighted average sales price; actual sales prices ranged from $139.11 to $140.07. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F5: Price reflects weighted average sales price; actual sales prices ranged from $140.12 to $141.11. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F6: Price reflects weighted average sales price; actual sales prices ranged from $141.12 to $141.85. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F7: Price reflects weighted average sales price; actual sales prices ranged from $142.28 to $143.26. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F8: Price reflects weighted average sales price; actual sales prices ranged from $143.28 to $144.265. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F9: Price reflects weighted average sales price; actual sales prices ranged from $144.286 to $144.80. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F10: Includes the following: (1) 18,768 unvested restricted share units ("RSUs"), which will vest in two equal annual installments beginning on June 12, 2026; (2) 21,964 unvested RSUs, which will vest in three equal annual installments beginning on June 12, 2026; (3) 14,574 unvested RSUs, which will vest on June 14, 2026; (4) 10,532 unvested RSUs, which will vest in two equal annual installments beginning on August 15, 2026; and (5) 72,578 unvested RSUs, which will vest on September 25, 2027.
• F11: Each unvested RSU represents a contingent right to receive one unrestricted, fully transferable share for each vested RSU which has not been previously forfeited.